SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Pola, P.
Right arrow Articles by Gerardino, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pola, P.
Right arrow Articles by Gerardino, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

New Prospects for the Treatment of Raynaud's Phenomenon Using A Serotoninergic S2 Receptor Antagonist (Ketanserin) and Stable Derivatives of Prostacyclin

Paolo Pola

he Department of Angiology, Catholic University of Sacred Heart, Rome, Italy

Paolo Tondi

he Department of Angiology, Catholic University of Sacred Heart, Rome, Italy

Michele Serricchio

he Department of Angiology, Catholic University of Sacred Heart, Rome, Italy

Angela Favuzzi

he Department of Angiology, Catholic University of Sacred Heart, Rome, Italy

Laura Gerardino

he Department of Angiology, Catholic University of Sacred Heart, Rome, Italy

The authors propose a promising new therapy for the treatment of Raynaud's phenomenon, with parenteral prostacyclin (carbaprostacycline) and a serotonergic S2-receptor antagonist (ketanserin) given orally. They studied 31 patients, 22 treated with ketanserin and carbaprostacycline, 9 with carbaprostacycline alone. Both groups demonstrated successful results and a significant improvement in measurements performed by photoplethysmography and transcutaneous pulse oxymetry.

Angiology, Vol. 44, No. 2, 123-128 (1993)
DOI: 10.1177/000331979304400206
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement